DataVXAdvanced SciencePaper
journal article·2026-06Open access

A Nanobody‐LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy

Shugang Qin, Zhiying Huang, Hai Huang, Yupei Zhang, Yuting Chen, Xi He, Zhenyi Niu, Zhongzheng Xiang, Chaoyu Zou, Xiangrong Song

Advanced Science· Volume 13· Issue 34
Publisher pageOpen full text
Source abstract

Abstract

ABSTRACT Effective cancer immunotherapy requires not only efficient antigen delivery to dendritic cells (DCs) but also overcoming local immunosuppression. Here, we introduce a nanobody‐LNP platform that achieves both targeting and active relicensing of DCs. By decorating lipid nanoparticles with nanobodies against the DC surface protein Plastin‐2 (PLS2), our platform achieves a remarkable 93% internalization efficiency. This preferential targeting dramatically enhances antigen expression while simultaneously relicensing DCs toward a more potent, mature phenotype by inhibiting the immunosuppressive Leptin‐JAK2‐STAT3 signaling pathway. This integrated strategy unleashed potent cytotoxic T lymphocyte responses and led to marked inhibition of established tumors. Our work establishes PLS2 as a novel immunomodulatory receptor and presents a dual‐action delivery platform that significantly boosts cancer vaccine potency.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Critical Care Medicine Frontiers Science Center for Disease‐related Molecular Network State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University Chengdu China

Department of Experimental Research Sichuan Clinical Research Center for Cancer Sichuan Cancer Center Sichuan Cancer Hospital & Institute University of Electronic Science and Technology of China Chengdu China

Department of Head and Neck Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center University of Electronic Science and Technology of China Chengdu China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.1126/sciadv.adn996110.1126/sciadv.adn9961 ↗
2. 10.1126/scitranslmed.adw072110.1126/scitranslmed.adw0721 ↗
3. 10.1038/s41586‐024‐08507‐510.1038/s41586‐024‐08507‐5 ↗
4. 10.1038/s41586‐023‐06063‐y10.1038/s41586‐023‐06063‐y ↗
5. 10.1038/s41571‐024‐00902‐110.1038/s41571‐024‐00902‐1 ↗
6. 10.1016/j.xcrm.2025.10198110.1016/j.xcrm.2025.101981 ↗
7. 10.1038/s41551‐024‐01208‐410.1038/s41551‐024‐01208‐4 ↗
8. 10.1001/jamaoncol.2022.537010.1001/jamaoncol.2022.5370 ↗
9. 10.1038/s41467-024-45358-010.1038/s41467-024-45358-0 ↗
10. 10.1016/j.jconrel.2025.11389110.1016/j.jconrel.2025.113891 ↗
11. 10.1002/anie.20231851510.1002/anie.202318515 ↗
12. 10.1021/jacs.4c1568810.1021/jacs.4c15688 ↗
13. 10.1038/s41467‐024‐53914‐x10.1038/s41467‐024‐53914‐x ↗
14. 10.1126/sciadv.add462310.1126/sciadv.add4623 ↗
15. 10.1038/s41565-025-01954-910.1038/s41565-025-01954-9 ↗
16. 10.1126/science.ade696710.1126/science.ade6967 ↗
17. 10.1002/adhm.20250060510.1002/adhm.202500605 ↗
18. 10.1038/s41551-025-01425-510.1038/s41551-025-01425-5 ↗
19. 10.1038/s41591‐022‐01937‐610.1038/s41591‐022‐01937‐6 ↗
20. 10.1016/j.cell.2024.04.00310.1016/j.cell.2024.04.003 ↗
21. 10.1038/s41591‐024‐03334‐710.1038/s41591‐024‐03334‐7 ↗
22. 10.1038/s41565‐023‐01548‐310.1038/s41565‐023‐01548‐3 ↗
23. 10.1056/NEJMoa210952210.1056/NEJMoa2109522 ↗
24. 10.1126/scitranslmed.abq441910.1126/scitranslmed.abq4419 ↗
25. 10.7150/thno.3494110.7150/thno.34941 ↗
26. 10.2967/jnumed.109.07007810.2967/jnumed.109.070078 ↗
27. 10.1016/j.jconrel.2023.07.02110.1016/j.jconrel.2023.07.021 ↗
28. 10.1038/s41467‐024‐53569‐810.1038/s41467‐024‐53569‐8 ↗
29. 10.1073/pnas.211627111910.1073/pnas.2116271119 ↗
30. 10.1038/s41467‐023‐39768‐910.1038/s41467‐023‐39768‐9 ↗
31. 10.1021/acsnano.8b0180610.1021/acsnano.8b01806 ↗
32. 10.1038/s41419‐023‐06391‐x10.1038/s41419‐023‐06391‐x ↗
33. 10.1038/gt.2011.20610.1038/gt.2011.206 ↗
34. 10.1186/1476‐4598‐13‐1010.1186/1476‐4598‐13‐10 ↗
35. 10.1126/sciadv.abq350010.1126/sciadv.abq3500 ↗
36. 10.1016/S1470‐2045(22)00372‐210.1016/S1470‐2045(22)00372‐2 ↗
37. 10.1016/j.jconrel.2023.11.00810.1016/j.jconrel.2023.11.008 ↗
38. 10.1038/s41586‐024‐08508‐410.1038/s41586‐024‐08508‐4 ↗
39. 10.1038/ni.166210.1038/ni.1662 ↗
40. 10.1038/nri.2016.11610.1038/nri.2016.116 ↗
41. 10.1016/j.molimm.2016.08.01210.1016/j.molimm.2016.08.012 ↗
42. Actin‐Bundling Protein L‐Plastin Promotes Megakaryocyte Rigidity And Dampens Proplatelet Formation
43. 10.1038/aps.2017.9910.1038/aps.2017.99 ↗
44. 10.4049/jimmunol.175.7.433810.4049/jimmunol.175.7.4338 ↗
45. 10.1016/j.cell.2022.09.02310.1016/j.cell.2022.09.023 ↗
46. 10.1002/adfm.20220469210.1002/adfm.202204692 ↗
47. 10.1016/j.apsb.2023.01.01010.1016/j.apsb.2023.01.010 ↗